Van Natta Mark L

Kempen John H, Van Natta Mark L, Friedman David S, Altaweel Michael M, Ansari Husam, Dunn James P et al.

This study found fluocinolone implants cause substantially higher glaucoma risk than systemic therapy in uveitis patients. Careful, indefinite IOP monitoring is crucial, as some glaucoma worsened despite expert management.

Ashraf Davin C, May K Patrick, Holland Gary N, Van Natta Mark L, Wu Albert W, Thorne Jennifer E et al.

HIV-NRD significantly lowers vision-specific quality of life in people with AIDS, even with good acuity. This highlights the importance of assessing contrast sensitivity and QOL in HIV patients.

Jabs Douglas A, Ahuja Alka, Van Natta Mark L, Lyon Alice T, Yeh Steven, Danis Ronald

This study found immune recovery in AIDS patients with CMV retinitis dramatically improves survival, while visual impairment and blindness rates are low, especially compared to the pre-cART era.

Jabs Douglas A, Drye Lea, Van Natta Mark L, Thorne Jennifer E, Holland Gary N

This study found HIV neuroretinal disorder is common in AIDS patients, increasing mortality and visual impairment risk, highlighting its significant long-term impact despite treatment.

Thorne Jennifer E, Van Natta Mark L, Jabs Douglas A, Duncan Jacque L, Srivastava Sunil K

This study found visual field loss in CMV retinitis patients is 6x lower with HAART, and immune recovery significantly reduces this risk, highlighting the importance of immune status.

Freeman William R, Van Natta Mark L, Jabs Douglas, Sample Pamela A, Sadun Alfredo A, Thorne Jennifer et al.

This study found significant vision loss, especially visual field defects (nearly 40%), in AIDS patients without retinitis, correlating with overall disease severity, highlighting a common, unexplained ocular complication.